NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsHighPositive
Announced Tue, 12 May · 17:50 IST

Neuland Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 24-Jul-2026.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹17100.00
prior close
₹18305.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.3-4.7-4.7-4.3-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0
Up moveDown movePending
AI summary

Neuland Laboratories reported strong FY2025-26 results with revenue from operations growing 37% to Rs 2,02,299 lakhs from Rs 1,47,684 lakhs. Consolidated profit after tax jumped nearly 40% to Rs 36,400 lakhs, while EBITDA margin expanded from 22.6% to 28.6%. The board recommended a final dividend of Rs 34 per share (340%) with record date July 24, 2026. Key developments include appointment of Dr. Mauricio Futran as Additional Director and approval for capacity expansion at Unit 1 with an investment of Rs 143.4 crores to meet growing customer demand. The statutory auditors issued unmodified opinions on both standalone and consolidated financial statements.

Likely market impact

The company delivered robust double-digit revenue and profit growth with improving margins, signaling strong operational performance. The dividend announcement and capacity expansion plan indicate confidence in future growth prospects, which should be positive for shareholder returns.